Biotechnology firm Creative Biolabs has unveiled advanced research technologies designed to support COVID-19 drug and vaccine development, focusing on the virus's critical spike protein mechanism. The company's innovative approaches offer researchers more efficient and safer methods for investigating potential treatments.
A key breakthrough is the pseudovirus neutralization assay, which allows scientists to test antiviral drugs and antibodies without using live, dangerous virus samples. Unlike traditional methods requiring biosafety level 3 laboratories, this technique enables experiments in standard research environments, significantly reducing experimental risks.
The company has also developed stable cell lines expressing SARS-CoV-2 spike proteins, which are crucial for vaccine development and drug research. These cell lines facilitate extensive antibody screening, receptor binding studies, and drug evaluation with improved experimental reliability and reduced research timelines.
Additionally, Creative Biolabs introduced a virus-like particle (VLP) vaccine platform utilizing a modified vaccinia Ankara vector. This approach produces vaccine candidates that can induce strong immune responses without infection risks, potentially offering more adaptable protection against emerging COVID-19 variants.
These technological advancements represent significant progress in COVID-19 research, providing researchers with more sophisticated tools to understand viral mechanisms and develop potential treatments. By simplifying complex research processes and enhancing experimental safety, Creative Biolabs is contributing to global efforts to combat the ongoing pandemic.
